Cell MedX Corp
Cell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System fo… Read more
Cell MedX Corp (CMXC) - Net Assets
Latest net assets as of November 2024: $-982.71K USD
Based on the latest financial reports, Cell MedX Corp (CMXC) has net assets worth $-982.71K USD as of November 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($38.35K) and total liabilities ($1.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-982.71K |
| % of Total Assets | -2562.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Cell MedX Corp - Net Assets Trend (2013–2024)
This chart illustrates how Cell MedX Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cell MedX Corp (2013–2024)
The table below shows the annual net assets of Cell MedX Corp from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-05-31 | $-826.46K | +65.35% |
| 2023-05-31 | $-2.39 Million | -18.74% |
| 2022-05-31 | $-2.01 Million | -27.47% |
| 2021-05-31 | $-1.58 Million | -3.66% |
| 2020-05-31 | $-1.52 Million | +14.23% |
| 2019-05-31 | $-1.77 Million | -65.13% |
| 2018-05-31 | $-1.07 Million | +8.20% |
| 2017-05-31 | $-1.17 Million | +17.22% |
| 2016-05-31 | $-1.41 Million | -106.49% |
| 2015-05-31 | $-684.07K | -3254.09% |
| 2014-05-31 | $-20.39K | -991.81% |
| 2013-05-31 | $-1.87K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cell MedX Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1023049500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $9.47 Million | % |
| Total Equity | $-826.46K | 100.00% |
Cell MedX Corp Competitors by Market Cap
The table below lists competitors of Cell MedX Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SKY LIGHT HOLDINGS LTD
F:27L
|
$27.11 Million |
|
Western Acquisition Ventures Corp
NASDAQ:WAVS
|
$27.11 Million |
|
Shinhan 11th Special Purpose Acquisition Company Co., Ltd.
KQ:452980
|
$27.11 Million |
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
$27.13 Million |
|
Topview Optronics Corporation
TWO:6556
|
$27.10 Million |
|
Foods & Inns Limited
NSE:FOODSIN
|
$27.08 Million |
|
Union Materials Corp
KO:047400
|
$27.07 Million |
|
HYUNDAI BIOLAND Co.Ltd
KQ:052260
|
$27.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cell MedX Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,385,480 to -826,455, a change of 1,559,025.
- Net loss of 142,486 reduced equity.
- Other factors increased equity by 1,701,511.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-142.49K | -17.24% |
| Other Changes | $1.70 Million | +205.88% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cell MedX Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-05-31 | $-0.03 | $0.43 | x |
| 2018-05-31 | $-0.02 | $0.43 | x |
| 2019-05-31 | $-0.04 | $0.43 | x |
| 2020-05-31 | $-0.03 | $0.43 | x |
| 2021-05-31 | $-0.03 | $0.43 | x |
| 2022-05-31 | $-0.48 | $0.43 | x |
| 2023-05-31 | $-0.04 | $0.43 | x |
| 2024-05-31 | $-0.04 | $0.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cell MedX Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.45K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.49K |
| 2015 | 0.00% | -2421.56% | 0.92x | 0.00x | $-963.76K |
| 2016 | 0.00% | -5851.51% | 0.14x | 0.00x | $-2.00 Million |
| 2017 | 0.00% | -20087.56% | 0.02x | 0.00x | $-1.13 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.44 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-728.73K |
| 2020 | 0.00% | -1140.32% | 0.60x | 0.00x | $-940.66K |
| 2021 | 0.00% | -13469.92% | 0.13x | 0.00x | $-753.23K |
| 2022 | 0.00% | -11498.42% | 0.15x | 0.00x | $-496.48K |
| 2023 | 0.00% | -17923.32% | 0.03x | 0.00x | $-256.49K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-59.84K |
Industry Comparison
This section compares Cell MedX Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cell MedX Corp (CMXC) | $-982.71K | 0.00% | N/A | $27.10 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |